VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SITC 2021 | Latest developments in radiopharmaceutical therapies

Ian A. Wilson • 12 Nov 2021
SITC 2021
Gastrointestinal Cancer General Genitourinary Cancer Gynecological Cancer Ovarian Cancer Pancreatic Cancer Prostate Cancer Antibodies
Immuno-Oncology Radiotherapy

Ian A. Wilson, PhD, ImaginAb Inc., Los Angeles, CA, gives an overview of ongoing work in radiopharmaceutical therapies. Specifically discussed is the pairing of a CD8 antibody fragment with a radioisotope to produce targeted radiotherapy. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

More from Ian A. Wilson

0:41
Next steps for the CD8 ImmunoPET minibody
Ian A. Wilson • 12 Nov 2021
1:09
Addressing unmet clinical needs with the CD8 ImmunoPET minibody
Ian A. Wilson • 12 Nov 2021

Related Videos

1:45
Mechanism of action of the adenovirus oncolytic virus CG0070 plus pembrolizumab in bladder cancer
Roger Li • 23 May 2022
1:55
Durvalumab monotherapy for patients with BCG-unresponsive carcinoma-in-situ bladder cancer
Roger Li • 23 May 2022
2:08
CORE1 trial: CG0070 plus pembrolizumab for BCG-unresponsive carcinoma-in-situ bladder cancer
Roger Li • 23 May 2022
1:17
The importance of Patient Reported Outcomes in clinical trials
Pedro Lara • 16 May 2022
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals